In yesterday’s Wall Street session, Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) shares traded at $0.41, down -1.87% from the previous session.
As of this writing, 3 analysts cover Aridis Pharmaceuticals Inc. (NASDAQ:ARDS). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $2.00, we find $6.00. Given the previous closing price of $0.42, this indicates a potential upside of 1328.57 percent. ARDS stock price is now -49.88% away from the 50-day moving average and -64.01% away from the 200-day moving average. The market capitalization of the company currently stands at $8.66M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
There are 1 analysts who have given it a hold rating, whereas 2 have given it a buy rating. Brokers who have rated the stock have averaged $6.00 as their price target over the next twelve months.
With the price target of $18, ROTH Capital recently initiated with Buy rating for Aridis Pharmaceuticals Inc. (NASDAQ: ARDS).
A total of 40.26% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ARDS stock. A new stake in Aridis Pharmaceuticals Inc. shares was purchased by ARMISTICE CAPITAL, LLC during the first quarter worth $856,000. EP WEALTH ADVISORS, LLC invested $21,000 in shares of ARDS during the first quarter. In the first quarter, B. RILEY WEALTH MANAGEMENT, INC. acquired a new stake in Aridis Pharmaceuticals Inc. valued at approximately $4,000. In total, there are 21 active investors with 10.20% ownership of the company’s stock.
Wednesday morning saw Aridis Pharmaceuticals Inc. (NASDAQ: ARDS) opened at $0.3957. During the past 12 months, Aridis Pharmaceuticals Inc. has had a low of $0.35 and a high of $2.77. The fifty day moving average price for ARDS is $0.8108 and a two-hundred day moving average price translates $1.1474 for the stock.
The latest earnings results from Aridis Pharmaceuticals Inc. (NASDAQ: ARDS) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.47, missing analysts’ expectations of -$0.17 by -0.3. This compares to -$1.69 EPS in the same period last year. The company reported revenue of $0.4 million for the quarter, compared to $0.52 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -22.52 percent. For the current quarter, analysts expect ARDS to generate $310k in revenue.
Aridis Pharmaceuticals Inc.(ARDS) Company Profile
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
Leave a Reply